SIBN

$12.84

Post-MarketAs of Mar 17, 8:00 PM UTC

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$12.84
Potential Upside
5%
Whystock Fair Value$13.48
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented tita...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$567.08M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-10.97%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
7.05

Recent News

Insider Monkey
Mar 13, 2026

Jim Cramer on SI-BONE, Inc.: “We’re Not Going to Buy the Money Losers”

SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer answered questions about. Inquiring about the stock, a caller mentioned that it has declined around 30% since they last asked about it in January. In response, Cramer said: Gee, I don’t know. That’s, whoa, they’re losing too much money. We’re in a tough tape. We’re […]

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Moby
Feb 24, 2026

SI-BONE, Inc. Q4 2025 Earnings Call Summary

Moby summary of SI-BONE, Inc.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Medical Device Network
Feb 24, 2026

Smith+Nephew, SI-BONE partner to distribute iFuse TORQ portfolio

The iFuse TORQ portfolio includes the iFuse TORQ TNT and iFuse TORQ implants.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
GuruFocus.com
Feb 24, 2026

SI-BONE Inc (SIBN) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Partnerships ...

SI-BONE Inc (SIBN) reports robust revenue growth and strategic initiatives, setting the stage for continued expansion in 2026 despite anticipated challenges.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Feb 24, 2026

Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of +69.23% and +0.09%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.